Opioid-salsolinol relationship in the control of prolactin release during lactation.
Endogenous opioid peptides (EOP) and dopamine (DA)-derived salsolinol are implicated in the suckling-induced prolactin surge. The aim of this study was to investigate the relationship between the opioidergic and salsolinergic activity in the mediobasal hypothalamus of nursing sheep. The sheep were infused intracerebroventricularly with opioid receptors antagonists: naloxone (all types of receptors, n=6); naloxonazine (μ receptor, n=6) or the vehicle (control, n=6) in a series of five 30-min infusions (60 μg/60 μl) from 10:00 to 15:00, at 30-min intervals. The period of the experiment included the non-suckling (10:00-12:30) and suckling (12:30-15:00) periods. Simultaneously, a push-pull perfusion of the infundibular nucleus/median eminence was performed in every sheep to study the dopaminergic system activity. Blood samples were also collected at 10-minute intervals to determine plasma prolactin concentration. Both the mean perfusate salsolinol and plasma prolactin concentrations were higher during the suckling vs. non-suckling (P<0.001) period in the control. The perfusate DA concentration was below the detection limit in this group. Treatment with either naloxone or naloxonazine significantly (P<0.01) diminished plasma prolactin concentration, as compared with the controls and blocked the prolactin surge during suckling. In drug-infused sheep, the perfusate salsolinol concentration was below the detection limit but the increased DA and its metabolite 3,4-dihydroxyphenylacetic acid concentrations were observed. In conclusion, the stimulatory action of EOP on prolactin secretion in nursing females is mediated, at least in part, by salsolinol, and the ligands for μ opioid receptor may be the primary factors of this relationship, especially with respect to the suckling-induced prolactin surge.
Misztal
T
T
Department of Endocrinology, The Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of Sciences, Instytucka 3 St., 05-110 Jablonna n/Warsaw, Poland. t.misztal@ifzz.pan.pl
Tomaszewska-Zaremba
D
D
Górski
K
K
Romanowicz
K
K
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D000833:Animals, Suckling; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D005260:Female; D007546:Isoquinolines / Q000378:metabolism*; D007774:Lactation; D009270:Naloxone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors; D012756:Sheep
D007546:Isoquinolines; D009292:Narcotic Antagonists; D017450:Receptors, Opioid, mu; D015102:3,4-Dihydroxyphenylacetic Acid; D009270:Naloxone; C034643:naloxonazine; D011388:Prolactin; C036617:salsolinol; D004298:Dopamine